Ertapenem

C difficile risk
Medium
Oral Bioavailability
N/A

Dosing

1g IV q24h

eGFR 0- 30eGFR > 30500mg IV q24h1g IV q24h

500mg IV daily

Dose after dialysis on HD days

General Information

Targeted therapy of ESBL infections and other resistant gram negative infections.

Empiric therapy when broad spectrum of carbapenems is desired without the need for anti-pseudomonal activity.

  • Immediate and delayed-type allergy

  • GI disturbance

  • Cytopenias, eosinophilia, positive Coombs

  • Liver enzyme abnormalities

  • Seizure risk lower than other carbapenems

Antimicrobial class: Carbapenem

Pregnancy category: B

Average serum half life: 4 hours

Urine penetration: Therapeutic

Lung penetration: Therapeutic

Biliary penetration: Moderate

Terms of Use | Feedback
© Copyright 2021 Spectrum Mobile Health Inc., dba Firstline Clinical. All rights reserved.